Evidence map›Paper›PMID 40394374›Full record

Trial reportInternational journal of hematology2025

A phase 2 trial of VRD induction for transplant-eligible Japanese patients with newly diagnosed multiple myeloma.

Ikuyo Tsutsumi, Masahide Yamamoto, Takayuki Fujio, Nobuharu Kosugi, Gaku Oshikawa, Koh Yamamoto, Takasi Kumagai, Toru Miki, Daisuke Kudo, Shigeo Toyota and 8 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ikuyo TsutsumiDepartment of Hematology, NHO Mito Medical Center, 280 Sakuranosato, Ibarakimachi, Higashiibaraki-gun, Ibaraki, 311-3193, Japan. ikuyo.ota@gmail.com.ORCID http://orcid.org/0000-0002-2675-7090
Masahide YamamotoDepartment of Hematology, Institute of Science Tokyo, Hospital, Tokyo, Japan.
Takayuki FujioDepartment of Hematology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Nobuharu KosugiDepartment of Internal Medicine, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Gaku OshikawaDepartment of Hematology, Japanese Red Cross Musashino Hospital, Musashino, Japan.
Koh YamamotoDepartment of Hematology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan.
Takasi KumagaiDepartment of Hematology, Ome Medical Center, Ome, Japan.
Toru MikiDepartment of Internal Medicine, Flowers & Forest Tokyo Hospital, Tokyo, Japan.
Daisuke KudoDepartment of Hematology, Hitachi General Hospital, Hitachi, Japan.
Shigeo ToyotaDepartment of Hematology, Yokosuka Kyosai Hospital, Yokosuka, Japan.
Yuichi NakamuraDepartment of Hematology, Saitama Medical University Hospital, Saitama, Japan.
Nobutaka KawaiDepartment of Hemato-oncology, International Medical Center, Saitama Medical University, Saitama, Japan.
Masao HagiwaraDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.
Takeshi KobayashiDivision of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Ayako AraiDepartment of Hematology, St. Marianna University Hospital, Kawasaki, Japan.
Takuya KomenoDepartment of Hematology, NHO Mito Medical Center, 280 Sakuranosato, Ibarakimachi, Higashiibaraki-gun, Ibaraki, 311-3193, Japan.
Hiroshi KojimaDepartment of Medical Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.
Ochanomizu Hematology Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This single-arm phase 2 trial investigated the efficacy and safety of bortezomib-lenalidomide-dexamethasone (VRD) induction for transplant-eligible Japanese patients with newly diagnosed multiple myeloma. Treatment consisted of four cycles of VRD (bortezomib 1.3 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaAdultAgedBortezomibDexamethasoneFemaleHumansInduction ChemotherapyJapanLenalidomideMaleMiddle AgedQuality of LifeThalidomideTreatment OutcomeBortezomibDexamethasoneLenalidomideThalidomideASCTBortezomibDexamethasoneLenalidomideMyeloma

Identifiers

PMID40394374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.